CN115282181A - Application of pueraria flower extract - Google Patents
Application of pueraria flower extract Download PDFInfo
- Publication number
- CN115282181A CN115282181A CN202210964898.9A CN202210964898A CN115282181A CN 115282181 A CN115282181 A CN 115282181A CN 202210964898 A CN202210964898 A CN 202210964898A CN 115282181 A CN115282181 A CN 115282181A
- Authority
- CN
- China
- Prior art keywords
- pueraria
- flower extract
- health
- extract
- pueraria flower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000219780 Pueraria Species 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 11
- 208000019423 liver disease Diseases 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 230000003213 activating effect Effects 0.000 claims abstract description 7
- 210000000952 spleen Anatomy 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 claims abstract description 6
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims abstract description 5
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims abstract description 5
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 6
- 206010019133 Hangover Diseases 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 6
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 9
- 241000628997 Flos Species 0.000 abstract description 7
- 208000007848 Alcoholism Diseases 0.000 abstract description 5
- 201000007930 alcohol dependence Diseases 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 description 20
- 238000010586 diagram Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Addiction (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses application of a pueraria flower extract in preparing a medicine and/or health-care product for preventing and/or treating liver diseases. The application of the pueraria flower extract in preparing the medicines and/or health care products for regulating the four levels of liver weight and blood fat. The pueraria flower serving as a traditional anti-alcoholism traditional Chinese medicine has wide clinical research, but the research is focused on the research of the pueraria flower compound traditional Chinese medicine for treating alcoholic fatty liver, and the research on the application of the pueraria flower single medicine in the medicines and/or health-care products for preventing and/or treating liver diseases is less. Use of flos Puerariae Lobatae extract in preparing medicine and/or health product for regulating AST, ALT, endotoxin LPS concentration and proinflammatory factor level is provided. The invention discloses a pueraria flower extract which can achieve the effects of relieving alcoholism and activating spleen by reducing mild inflammatory reaction.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of a pueraria flower extract.
Background
At present, the name of pueraria flower is traditional Chinese medicine. Is flower of Pueraria lobata (Willd.) Ohwi, pueraria thomsonii Benth. The distribution of the wild pueraria lobata is distributed all over the country except for Xinjiang and Tibet; gangevine is distributed in Guangdong, guangxi, sichuan and Yunnan provinces. Has effects of relieving alcoholic intoxication, activating spleen, and stopping bleeding, and can be used for treating alcoholic intoxication, dysphoria, thirst, headache, dizziness, abdominal distention, vomiting, acid regurgitation, anorexia, hematemesis, and intestinal wind with hemoptysis.
In the prior art, the pueraria flower extract is applied to improving intestinal tract dysbiosis, but research on the pueraria flower extract in preparing a medicament for preventing and treating liver diseases is not available.
Through the above analysis, the problems and defects of the prior art are as follows: the prior art has not researched the preparation of the medicine for preventing and treating liver diseases by the pueraria flower extract.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides the application of the pueraria flower extract.
The invention is realized by the application of the pueraria flower extract in preparing medicines and/or health-care products for preventing and/or treating liver diseases.
Further, the liver disease is alcoholic fatty liver.
Further, the application of the pueraria flower extract in preparing medicines and/or health-care products for regulating the four levels of liver weight and blood fat.
Further, the application of the pueraria flower extract in preparing medicines and/or health care products for regulating AST, ALT, endotoxin LPS concentration and proinflammatory factor level.
Further, the application of the pueraria flower extract in preparing medicines and/or health-care products for reducing the inflammatory reaction.
Further, the application of the pueraria flower extract in preparing food and/or health-care products and/or medicines for relieving alcoholism and activating spleen.
Further, the application of the pueraria flower extract in preparing foods and/or health-care products and/or medicines for preventing drunkenness, dispelling effects of alcohol and protecting liver.
In combination with the above technical solutions and the technical problems to be solved, please analyze the advantages and positive effects of the technical solutions to be protected in the present invention from the following aspects:
first, aiming at the technical problems existing in the prior art and the difficulty in solving the problems, the technical problems to be solved by the technical scheme of the present invention are closely combined with the technical scheme to be protected and the results and data in the research and development process, and some creative technical effects brought after the problems are solved are analyzed in detail and deeply. The specific description is as follows:
the invention discovers that the pueraria lobata extractive can effectively regulate four items of liver weight and blood fat in blood, AST and ALT, endotoxin LPS concentration and proinflammatory factor level in an AFLD mouse.
Secondly, considering the technical scheme as a whole or from the perspective of products, the technical effect and advantages of the technical scheme to be protected by the invention are specifically described as follows:
the invention discloses that the pueraria lobata flower extract achieves the effects of dispelling the effects of alcohol and activating the spleen by reducing the micro-inflammatory reaction through the correlation analysis of intestinal tract and liver omics.
Third, as an inventive supplementary proof of the claims of the present invention, there are also presented several important aspects:
the technical scheme of the invention fills the technical blank in the industry at home and abroad:
the pueraria flower serving as a traditional anti-alcoholism traditional Chinese medicine has wide clinical research, but the research is focused on the research of the pueraria flower compound traditional Chinese medicine for treating alcoholic fatty liver, and the research on the application of the pueraria flower single medicine in the medicines and/or health-care products for preventing and/or treating liver diseases is less.
Drawings
FIG. 1 is a schematic diagram of a model construction of a "multi-strike" type TP4030M3 liquid feed chronic alcohol AFLD mouse provided in an embodiment of the present invention;
FIG. 2 is a schematic diagram of mouse model of the intervention of flos Puerariae Lobatae extract in AFLD provided by the present invention;
FIG. 2 (A) is a schematic diagram of the weight change of a mouse model for AFLD, which is interfered by a pueraria flower extract provided by the embodiment of the invention;
FIG. 2 (B) is a schematic diagram of the interaction of pueraria lobata extract in the liver of an AFLD mouse model provided by the embodiment of the present invention;
FIG. 2 (C) is a schematic diagram of the intervention of the flos Puerariae Lobatae extract in the liver/body weight (%) of an AFLD mouse model provided by the present invention;
FIG. 2 (D) is a schematic diagram of the intervention of pueraria lobata flower extract in LPS concentration in blood of an AFLD mouse model provided by the embodiment of the present invention;
FIG. 2 (E) is a graph showing the concentration of D-mannitol in a mouse model of AFLD mediated by flos Puerariae Lobatae extract according to an embodiment of the present invention;
FIG. 3 is a schematic diagram of the intervention of pueraria lobata extract in the blood inflammatory factor level of AFLD mice;
FIG. 3 (A) is a schematic diagram of the intervention of pueraria lobata flower extract in blood TNF-alpha level of AFLD mice;
FIG. 3 (B) is a schematic diagram of the interference of the pueraria lobata extract in the MCP-1 level in blood of AFLD mice provided by the embodiment of the invention;
FIG. 3 (C) is a schematic diagram of the intervention of pueraria lobata flower extract in blood IL-6 level of AFLD mice provided by the embodiment of the present invention;
FIG. 3 (D) is a schematic diagram of the intervention of pueraria lobata extract in blood IL-10 level of AFLD mice provided by the embodiment of the present invention;
FIG. 4 is a graph comparing the blood lipid level and liver function level of AFLD mice with the Kudzuvine flower extract;
FIG. 4 (A) is a schematic diagram of the interaction of pueraria lobata extract with the TC concentration in blood of an AFLD mouse according to an embodiment of the present invention;
FIG. 4 (B) is a schematic diagram of the interaction of pueraria lobata extract with the blood TG concentration of AFLD mice provided by the embodiment of the present invention;
FIG. 4 (C) is a schematic diagram of the intervention of the blood LDL-C concentration of AFLD mice by the pueraria lobata flower extract provided by the embodiment of the present invention;
FIG. 4 (D) is a schematic diagram of the intervention of pueraria lobata flower extract in the blood HDL-C concentration of AFLD mice provided by the embodiment of the present invention;
FIG. 4 (E) is a schematic diagram of the intervention of the pueraria lobata extract in the blood AST concentration of the AFLD mice provided by the embodiment of the invention;
FIG. 4 (F) is a graph showing the interaction of pueraria lobata extract with blood ALT concentration in AFLD mice according to the present invention;
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
1. Illustrative embodiments are explained. This section is an illustrative example developed to explain the claims in order to enable those skilled in the art to fully understand how to implement the present invention.
The application of the pueraria flower extract provided by the embodiment of the invention comprises the following steps: application of flos Puerariae Lobatae extract in preparing medicine and/or health product for preventing and/or treating liver diseases is provided.
The liver disease provided by the embodiment of the invention is alcoholic fatty liver.
The application of the pueraria flower extract provided by the embodiment of the invention in preparing medicines and/or health care products for regulating the four levels of liver weight and blood fat.
The pueraria lobata flower extract provided by the embodiment of the invention is used for preparing medicines and/or health care products for regulating AST, ALT, endotoxin LPS concentration and proinflammatory factor level.
The application of the pueraria flower extract provided by the embodiment of the invention in preparing a medicament and/or health-care product for reducing slight inflammatory reaction.
2. Application examples. In order to prove the creativity and the technical value of the technical scheme of the invention, the part is an application example of the technical scheme of the claims to a specific product or related technology.
The application embodiment of the invention provides application of a pueraria flower extract in preparation of food and/or health-care products and/or medicines for relieving alcoholism and activating spleen.
The application embodiment of the invention provides application of a pueraria flower extract in preparing food and/or health-care products and/or medicines for preventing drunkenness, dispelling effects of alcohol and protecting liver.
3. Evidence of the relevant effects of the examples. The embodiment of the invention achieves some positive effects in the process of research and development or use, and has great advantages compared with the prior art, and the following contents are described by combining data, diagrams and the like in the test process.
The pueraria lobata extract effectively protects the microenvironment of the middle intestine of an AFLD mouse model and prevents AFLD midgut-hepatic axis lesion.
Application TP4030M3: feeding Lieber-Decarli alcohol liquid feed (corn oil) liquid feed (Nantong Telofil feed science and technology Co., ltd.), and establishing a multiple-strike AFLD mouse model. The experimental animals are male SPF grade C57BL/6 mice (10 weeks old, weight more than 20 g) (Beijing Wintolite) and randomly grouped into 2 cages, and are raised in an SPF barrier environment, the temperature is controlled at 24 +/-1 ℃, the light and shade alternation time is 12/12h, and the humidity is controlled at about 70%.
Figure 2-figure 4 single factor analysis of variance significance; in fig. 2-4 () P < 0.05), ((P < 0.01) and (() P < 0.001).
In the wild AFLD mouse model, the results showed that: the flos Puerariae Lobatae extract is effective in regulating liver weight, blood lipid level, AST and ALT, endotoxin LPS concentration and proinflammatory factor level in AFLD mouse, as shown in figure 1-figure 4. This reveals that flos puerariae lobatae has effects of relieving hangover and activating spleen by alleviating micro-inflammatory reaction.
The above description is only for the purpose of illustrating the embodiments of the present invention, and the scope of the present invention should not be limited thereto, and any modifications, equivalents and improvements made by those skilled in the art within the technical scope of the present invention as disclosed in the present invention should be covered by the scope of the present invention.
Claims (7)
1. The application of the pueraria flower extract is characterized in that the pueraria flower extract is applied to preparing medicines and/or health-care products for preventing and/or treating liver diseases.
2. The use of a pueraria flower extract according to claim 1, wherein the liver disease is alcoholic fatty liver.
3. The use of the pueraria lobata flower extract as claimed in claim 1, wherein the pueraria lobata flower extract is used in the preparation of a medicament and/or health product for regulating four levels of liver weight and blood lipid.
4. Use of a pueraria flower extract according to claim 1, for the preparation of a medicament and/or health product for regulating AST, ALT, endotoxin LPS concentration and level of pro-inflammatory factors.
5. Use of a pueraria flower extract according to claim 1, in the preparation of a medicament and/or health product for reducing an inflammatory reaction.
6. The use of the pueraria lobata flower extract as claimed in claim 1, wherein the pueraria lobata flower extract is used in the preparation of foods and/or health products and/or medicines for alleviating hangover and activating the spleen.
7. The use of the pueraria lobata extract as claimed in claim 1, wherein the pueraria lobata extract is used in the preparation of foods and/or health products and/or medicines for preventing intoxication, alleviating hangover and protecting liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210964898.9A CN115282181A (en) | 2022-08-12 | 2022-08-12 | Application of pueraria flower extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210964898.9A CN115282181A (en) | 2022-08-12 | 2022-08-12 | Application of pueraria flower extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115282181A true CN115282181A (en) | 2022-11-04 |
Family
ID=83828896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210964898.9A Pending CN115282181A (en) | 2022-08-12 | 2022-08-12 | Application of pueraria flower extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115282181A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104644915A (en) * | 2015-01-22 | 2015-05-27 | 泸州医学院附属中医医院 | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition |
| CN114796307A (en) * | 2022-03-29 | 2022-07-29 | 甘肃中医药大学 | Application of flos puerariae lobatae extract in preparing medicine for preventing and treating inflammatory bowel diseases |
-
2022
- 2022-08-12 CN CN202210964898.9A patent/CN115282181A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104644915A (en) * | 2015-01-22 | 2015-05-27 | 泸州医学院附属中医医院 | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition |
| CN114796307A (en) * | 2022-03-29 | 2022-07-29 | 甘肃中医药大学 | Application of flos puerariae lobatae extract in preparing medicine for preventing and treating inflammatory bowel diseases |
Non-Patent Citations (2)
| Title |
|---|
| 张志强 等: "葛花的现代研究与思考", 中医学报, vol. 31, no. 12, pages 1957 - 1960 * |
| 王瑶等: "葛花不同提取物总黄酮含量与保肝作用药效关系研究", 山西中医, vol. 32, no. 09, pages 49 - 51 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101845362A (en) | Method for gathering oleic acid from tea-seed oil | |
| CN104304679B (en) | A kind of B B-complex C, E immune polysaccharide microemulsion preparation and its preparation method and application | |
| CN111110772A (en) | Solid state fermentation traditional Chinese medicine additive for preventing and controlling livestock and poultry parasites | |
| CN101279941A (en) | Preparation of florfenicol sodium succinate | |
| CN110201035B (en) | Plant essential oil composition for poultry and preparation method and application thereof | |
| CN102824417A (en) | New method for treating helicobacter pylori related diseases | |
| CN115282181A (en) | Application of pueraria flower extract | |
| CN107349238A (en) | A kind of auxiliary improvement of memory acer truncatum seed oil compound preparation and its application | |
| CN113069493A (en) | Application of oil tea extract in inhibiting sebum secretion | |
| CN1405314A (en) | Cryptoporus volvatus fermented product, and its preparation method and application | |
| CN101697774A (en) | Traditional Chinese medicine feed additive for treating chicken coccidiosis | |
| CN113398129B (en) | Application of trichophyton A in preparation of anxiolytic drugs | |
| CN106306548A (en) | Feed additive for preventing and treating chicken proventriculitis and ventriculitis | |
| CN102949298A (en) | Application of usnic acid and/or salts thereof | |
| CN113229369B (en) | sn-2 saturated fatty acid active structured lipid composition and preparation method and application thereof | |
| CN1842329A (en) | Preventive or ameliorating agent for liver disease involving hepatopathy | |
| CN1939465A (en) | Chinese-medicinal composition for treating fowl mycoplasmosis and mixed enteritis infection | |
| CN108936023A (en) | A kind of bouvardin and preparation method thereof for pannage | |
| CN110038090A (en) | A kind of compound celery oil self-emulsifying soft capsule and preparation method thereof with antigout effect | |
| CN1313499C (en) | Sargassum polysaccharide, its preparation method and use | |
| CN104222527A (en) | Application method of betulinic acid | |
| CN104208086A (en) | Application of astilbin or homolog thereof in preparation of drugs for treating psoriasis | |
| CN117298198B (en) | Microalgae extract and application thereof | |
| Nordstrand et al. | Organ changes in rats on complete parenteral nutrition | |
| CN115317534B (en) | Application of myrtle extract in reducing blood sugar and treating diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |